周边溃疡性角膜炎的临床结局
该回顾性病例系列纳入2003年1月至2022年10月在Wilmer眼科研究所诊断为周边溃疡性角膜炎(PUK)的57例患者,评估临床与治疗结局。中位随访3年期间,76%患者接受口服泼尼松、80%接受至少1种免疫抑制剂,所有患者均在中位1.3个月内达到疾病控制,但仅6%实现持续无药缓解。
要点
- 57例PUK患者中56%伴有系统性诊断,42%初诊时为双眼受累,81只患眼中7只在初诊前已穿孔。
- 中位随访3年,76%使用口服泼尼松、80%使用至少1种免疫抑制剂,全部患者在中位1.3个月内达到疾病控制。
- 减少激素成功率0.44/患者年、停用激素成功率0.27/患者年,仅6%实现持续无药缓解。
核心结论
- 在中位3年随访中,全身治疗实现了疾病控制、减少激素及停用激素,但本队列中持续无药缓解不常见。
研究设计与样本
- 回顾性病例系列,纳入2003年1月至2022年10月在Wilmer眼科研究所诊断为PUK的患者。
主要发现
- 共识别57例PUK患者,中位年龄53岁,46%为黑人,56%伴有系统性诊断,初诊前症状中位持续3个月,42%初诊时为双眼病变。
- 81只患眼中7只在初诊前已穿孔;中位随访3年,76%患者接受口服泼尼松,80%接受至少1种免疫抑制剂。
- 所有患者均在中位1.3个月内达到疾病控制;减少激素成功率为0.44/患者年,停用激素成功率为0.27/患者年。
- 仅6%患者实现持续无药缓解;随访期间角膜穿孔发生率为0.009/眼年,疾病复发率为0.07/眼年,中位复发时间约2年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate clinical and treatment outcomes in patients with peripheral ulcerative keratitis (PUK). DESIGN: Retrospective, case series SUBJECTS: Patients diagnosed with PUK at the Wilmer Eye Institute between January 2003 and October 2022. METHODS: Data collected included demographics, presence of systemic disease, disease laterality, duration of disease, PUK activity, presence of corneal perforation, and treatments. Outcomes of interest included: disease control, corticosteroid-sparing success, corticosteroid-discontinuation success, sustained drug-free remission, disease reactivation, occurrence of perforation, and need for surgery. RESULTS: Fifty-seven patients with PUK were identified. The median age was 53 years, with 46% of patients being Black. Most patients (56%) had an associated systemic diagnosis. The median duration of symptoms prior to presentation was 3 months and 42% of patients presented with bilateral disease. Of the 81 affected eyes, 7 had perforated prior to presentation. During a median follow-up of 3 years, 76% of patients received oral prednisone and 80% received at least 1 immunosuppressive drug. Disease control was achieved in all patients within a median of 1.3 months. The rates of corticosteroid-sparing success and corticosteroid discontinuation were 0.44 per patient-year (/PY) and 0.27/PY, respectively. Sustained drug-free remission was achieved in only 6% of patients. During follow-up, the rate of corneal perforation was 0.009/EY. The rate of disease reactivation was 0.07/EY, with a median time to reactivation of ∼2 years. CONCLUSIONS: Over a moderate amount of follow-up, systemic therapy achieved disease control, corticosteroid-sparing and corticosteroid discontinuation. However, sustained drug-free remission was infrequent in our cohort.
引用
- Mallem K, Liberman P, Berkenstock MK, et al. Clinical Outcomes in Peripheral Ulcerative Keratitis. Am J Ophthalmol. 2025. PMID: 39870340. doi:10.1016/j.ajo.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。